Friday, February 01, 2008 5:32:56 PM
Friday February 1, 4:56 pm ET
By Matthew Perrone, AP Business Writer
Medtronic Gets FDA Approval for Endeavor, First New Drug-Coated Stent in 4 Years
WASHINGTON (AP) -- Medtronic on Friday received federal approval to sell its drug-coated stent, the first to hit the U.S. market since safety concerns sank their popularity two years ago.
The Food and Drug Administration said it cleared the company's Endeavor stent for use in patients with clogged arteries. Medtronic said it expects to ship 100,000 units to hospitals in February.
Endeavor is one of a new generation of stents the industry hopes can rejuvenate U.S. demand for the drug-oozing devices, sales of which plummeted to $2 billion last year, down from a peak of $3.1 billion in 2005.
Stents are tiny, mesh-wire tubes that prop open arteries after they have been surgically cleared of fatty plaque. They became one of the most lucrative medical devices in modern history after companies began adding drug coatings to stents in 2003 to prevent blood clotting.
An estimated 6 million people worldwide have had one implanted.
Shares of Medtronic rose $1.35, or 2.9 percent, to $47.85 Friday.
A series of studies in 2006 showed that months after they're implanted, stent coatings have the potential to increase the risk of life-threatening blood clots unless patients continue to take anti-clotting drugs. Medical societies, such as the American College of Cardiology, urge patients to continue taking the drugs for at least a year after implantation.
In late 2006, a panel of federal advisers said that the majority of patients with the drug-coated stents have an increased risk of heart attack and death, though it's unclear whether their poor health or the drug coatings are to blame.
The percentage of stent patients receiving drug-coated versions versus the older, bare-metal models has fallen to an estimate 65 percent, from more than 80 percent, before 2006.
The new offering from Minneapolis-based Medtronic will compete with older stents from Johnson & Johnson and Boston Scientific Corp. -- two companies that cut thousands of jobs in recent months, partially because of lower stent sales.
And there's been more bad news for companies that sell stents as recently as last week. A study in the New England Journal of Medicine showed patients who underwent bypass surgery had fewer heart attacks than those who had stents implanted. The study dimmed hopes that less intrusive stenting would prove just as safe as surgery for people with clogged arteries.
Cleveland Clinic cardiologist Deepak Bhatt said it will probably be years before enough data is collected to definitively say whether one stent outperforms others.
"There's so many ways to slice and dice data that any one of these companies could probably find a way to claim superiority," said Bhatt, who directs Cleveland Clinic's cardiovascular center. "But the availability of new drug-eluting stents expands options for doctors and patients, which is always a good thing."
But not for Johnson & Johnson and Boston Scientific Inc, which account for 45 percent and 55 percent, respectively, of the U.S. market. The Endeavor is expected to capture about 20 percent of that space in 2008, according to projections from Morgan Stanley analyst Glenn Reicin.
Recent MDT News
- Medtronic to announce financial results for its fourth quarter and full fiscal year 2024 • PR Newswire (US) • 05/09/2024 12:45:00 PM
- Medtronic to announce financial results for its fourth quarter and full fiscal year 2024 • PR Newswire (Canada) • 05/09/2024 12:45:00 PM
- Medtronic receives FDA approval for Inceptiv™ closed-loop spinal cord stimulator • PR Newswire (US) • 04/26/2024 11:56:00 AM
- Medtronic receives FDA approval for Inceptiv™ closed-loop spinal cord stimulator • PR Newswire (Canada) • 04/26/2024 11:56:00 AM
- Americans favor quality over quantity in pursuit of longevity • PR Newswire (Canada) • 04/17/2024 11:02:00 AM
- Americans favor quality over quantity in pursuit of longevity • PR Newswire (US) • 04/17/2024 11:02:00 AM
- Medtronic unveils the future of AI in GI: Genius Summit 2024 reveals innovations and collaborations that advance endoscopic care • PR Newswire (Canada) • 04/10/2024 12:30:00 PM
- Medtronic unveils the future of AI in GI: Genius Summit 2024 reveals innovations and collaborations that advance endoscopic care • PR Newswire (US) • 04/10/2024 12:30:00 PM
- The Medtronic Sphere-360™ Pulse Field Ablation (PFA) catheter, a new paradigm in single-shot ablation, demonstrates impressive results in treating paroxysmal atrial fibrillation • PR Newswire (US) • 04/08/2024 12:00:00 PM
- The Medtronic Sphere-360™ Pulse Field Ablation (PFA) catheter, a new paradigm in single-shot ablation, demonstrates impressive results in treating paroxysmal atrial fibrillation • PR Newswire (Canada) • 04/08/2024 12:00:00 PM
- SMART trial one-year data demonstrates Medtronic Evolut™ TAVR platform as optimal treatment for severe aortic stenosis in patients with small annulus, which is primarily women • PR Newswire (US) • 04/07/2024 01:45:00 PM
- SMART trial one-year data demonstrates Medtronic Evolut™ TAVR platform as optimal treatment for severe aortic stenosis in patients with small annulus, which is primarily women • PR Newswire (Canada) • 04/07/2024 01:45:00 PM
- New survey uncovers lack of awareness around heart valve disease and risk factors among women • PR Newswire (Canada) • 04/07/2024 12:00:00 PM
- New survey uncovers lack of awareness around heart valve disease and risk factors among women • PR Newswire (US) • 04/07/2024 12:00:00 PM
- Medtronic announces FDA approval of newest-generation Evolut TAVR system for treatment of symptomatic severe aortic stenosis • PR Newswire (US) • 03/27/2024 12:00:00 PM
- Medtronic announces FDA approval of newest-generation Evolut TAVR system for treatment of symptomatic severe aortic stenosis • PR Newswire (Canada) • 03/27/2024 12:00:00 PM
- U.S. Patent Office rejects Axonics' latest challenge to Medtronic patents • PR Newswire (US) • 03/21/2024 06:51:00 PM
- U.S. Patent Office rejects Axonics' latest challenge to Medtronic patents • PR Newswire (Canada) • 03/21/2024 06:51:00 PM
- New real-world data shows MiniMed™ 780G system sustains strong global performance, exceeding international targets for diabetes management • PR Newswire (US) • 03/09/2024 10:40:00 AM
- Medtronic announces cash dividend for fourth quarter of fiscal year 2024 • PR Newswire (US) • 03/07/2024 09:20:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 07:18:56 PM
- Medtronic EVP & CFO Karen Parkhill to participate in the Barclays healthcare conference • PR Newswire (US) • 03/05/2024 09:30:00 PM
- Medtronic EVP & CFO Karen Parkhill to participate in the Barclays healthcare conference • PR Newswire (Canada) • 03/05/2024 09:30:00 PM
- Medtronic files ITC action against Axonics to stop unauthorized use of Medtronic innovations • PR Newswire (US) • 02/29/2024 02:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/27/2024 09:16:45 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM